NYSEHealth CareHealth Care EquipmentS&P MidCap 400S&P SmallCap 600
$224.41
+4.43 (+2.01%)
Close of Nov 06, 2026 · end-of-day data
GKOS 8-K filings in 2024
Every material Form 8-K Glaukos filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Glaukos entered into agreements on December 2, 2024 to early terminate a portion of capped call transactions linked to its $287.5 million 2.75% Convertible Senior Notes due 2027. The counterparties will pay the company a cash amount based on the average share price over an averaging period starting December 3, 2024, and the filing gives no figure for that amount.
Unwind covers capped calls for 50% of the shares underlying the Notes.
Notes have an aggregate principal amount of $287.5 million and a 2.75% coupon, due 2027.
Cash settlement amount depends on the volume-weighted average share price during an averaging period starting December 3, 2024.
Form of Capped Call Unwind Agreement filed as Exhibit 10.1.
Glaukos reported third-quarter 2024 net sales of $96.7 million, up 24% from a year earlier, and narrowed its net loss to $21.4 million from $30.4 million. The company raised its full-year 2024 net sales guidance to $377 million to $379 million from $370 million to $376 million, which is a positive signal for shareholders on revenue trend, though the company still reported a GAAP net loss.
Q3 2024 net sales of $96.7 million, up 24% year over year; glaucoma sales $76.0 million, up 30%
Q3 2024 net loss of $21.4 million, or $0.39 per diluted share, versus $30.4 million, or $0.63, in Q3 2023
2024 net sales guidance raised to $377 million to $379 million from $370 million to $376 million
Cash, short-term investments and restricted cash of $267.2 million as of September 30, 2024
Glaukos reported second-quarter 2024 net sales of $95.7 million, up 19% from a year earlier, and raised its full-year 2024 net sales guidance to $370 million to $376 million from $357 million to $365 million. GAAP net loss widened to $53.9 million, or $1.06 per diluted share, from $32.8 million, or $0.68 per share, a year earlier, including an $18.0 million charge tied to convertible senior note exchanges.
Q2 2024 net sales of $95.7 million, up from $80.4 million in Q2 2023
GAAP net loss of $53.9 million, or $1.06 per diluted share, versus $32.8 million, or $0.68, in Q2 2023
2024 net sales guidance raised to $370 million to $376 million from $357 million to $365 million
$18.0 million charges associated with convertible senior notes; cash and investments of $266.4 million as of June 30, 2024
At its May 30, 2024 annual meeting, Glaukos stockholders approved the Amended and Restated 2015 Omnibus Incentive Compensation Plan, which cuts the shares available for awards by about 7.9 million, extends the plan to May 30, 2034, and removes the evergreen feature. Stockholders also elected three Class III directors and ratified Ernst & Young LLP as the independent auditor for 2024, so the filing mainly records governance decisions rather than a change in financial results.
Restated plan approved: 31,369,389 votes for, 13,791,781 against, 137,272 abstentions, and 2,441,003 broker non-votes
Available share pool reduced by approximately 7.9 million shares; plan term extended to May 30, 2034
Directors elected: Thomas W. Burns (43,130,097 for), Marc A. Stapley (35,495,121 for), Leana S. Wen, M.D. (43,596,144 for)
Ernst & Young LLP ratified as auditor for the year ending December 31, 2024, with 47,458,368 votes for
Glaukos reported first quarter 2024 net sales of $85.6 million, up 16% from $73.9 million a year earlier, and raised its full-year 2024 net sales guidance to $357 million to $365 million from $350 million to $360 million. The GAAP net loss widened to $40.8 million, or $0.82 per share, from $34.6 million, or $0.72 per share, in the same period of 2023, including an $11.7 million acquired in-process R&D charge that the company excluded from its non-GAAP results.
Q1 2024 net sales were $85.6 million, up 16% on both a reported and constant currency basis.
GAAP net loss was $40.8 million, or $(0.82) per diluted share, versus $34.6 million, or $(0.72), in Q1 2023.
Non-GAAP net loss was $34.6 million, or $(0.70) per diluted share, including an $11.7 million acquired in-process R&D charge.
Cash, cash equivalents, short-term investments and restricted cash were about $278.7 million as of March 31, 2024, versus $301.3 million at December 31, 2023.
Glaukos reported fourth-quarter 2023 net sales of $82.4 million, up 16% from a year earlier, and full-year net sales of $314.7 million, up 11%. Its net loss widened over the same periods, and the company reaffirmed 2024 net sales guidance of $350 million to $360 million, which shareholders will weigh against the higher losses.
Q4 2023 net sales of $82.4 million, up 16% reported and 15% constant currency versus Q4 2022
Q4 2023 net loss of $36.8 million, or $0.75 per diluted share, versus $31.5 million, or $0.66, a year earlier
Full-year 2023 net sales of $314.7 million, up 11%; net loss of $134.7 million, or $2.78 per share, versus $99.2 million, or $2.09, in 2022
2024 net sales guidance of $350 million to $360 million reaffirmed; cash, short-term investments and restricted cash were about $301 million at December 31, 2023
Glaukos said preliminary, unaudited net sales were expected to exceed $81 million for the fourth quarter and $313 million for fiscal 2023, compared with $283 million for 2022 as shown in its investor presentation. The company also reaffirmed its 2024 net sales guidance of $350 million to $360 million, so shareholders have a preliminary sales figure ahead of audited results and no change to the outlook.
Preliminary fourth-quarter 2023 net sales expected to be in excess of $81 million
Preliminary full-year 2023 net sales expected to be in excess of $313 million, versus $283 million in 2022 per the investor presentation
2024 net sales guidance reaffirmed at $350 million to $360 million
Figures are preliminary and unaudited, per the press release dated January 9, 2024
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Glaukos filing is on SEC EDGAR ↗. 8-K briefs of other companies →